<DOC>
	<DOCNO>NCT02811198</DOCNO>
	<brief_summary>The ultimate aim study identify biomarker suicide risk MDD measure `` hedonic spectrum '' ( pain reward responsivity ) , attention associate brain structure use brain scan ( fMRI DTI ) , well stability marker time .</brief_summary>
	<brief_title>Pain , Reward , Attention Neurocircuitry : Biomarkers Suicidality</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<criteria>1 . DSM5 criterion Major Depressive Episode within MDD , confirm MINI diagnosis104 2 . Ages 18 70 year 3 . Hamilton Depression Rating Scale 17 item ( HAMD17 ) &gt; 14 4 . Capable give informed consent 5 . Groups 1 2 participant : HAMD17 item 3 ( suicide ) &gt; 2 6 . Group 2 participant : positive history suicide attempt within last six month 7 . Group 3 participant : positive history lifetime suicide attempt 1 . Pregnancy/lactation 2 . Medical condition require immediate investigation treatment 3 . Recent ( &lt; 6 month ) /current history drug abuse/dependence ( caffeine , nicotine ) 4 . Lifetime history psychosis , Bipolar I Bipolar II ; Axis I comorbidities allowable 5 . No current Axis II diagnosis , confirm International Personality Disorder Examination ( IPDE ) 105 6 . Use stimulant , sedative hypnotic atypical antipsychotic within 2 week neuroimaging scan . Individuals receive benzodiazepine daily basis exclude study . Those receive benzodiazepine `` need '' basis ( take , every day ) receive atypical antipsychotic wash benzodiazepine/atypical antipsychotic two week prior neuroimaging . 7 . Participation experimental treatment trial study duration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>